Loncar Cancer Immunotherapy ETF (CNCR)
Loncar Cancer Immunotherapy ETF operates in the Asset Management industry of the Financial Services sector, headquartered in DE, US. The stock last traded at $9.02, up 1.58% on the session, giving a market capitalisation of $7.0M. Its beta of 0.96 implies it has historically moved less than the broad market.
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
Loncar Cancer Immunotherapy ETF is most often compared with the following Financial Services names: